A phase I evaluation of vandetanib plus paclitaxel, carboplatin, 5-fluorouracil, and XRT induction therapy followed by surgery for previously untreated locally advanced cancer of the esophagus and GE junction.
Astsaturov I, Meyer J, Cheng J, Olszanski A, Dushkin H, Berger A, Davey M, Cohen S, Burtness B, Scott W. A phase I evaluation of vandetanib plus paclitaxel, carboplatin, 5-fluorouracil, and XRT induction therapy followed by surgery for previously untreated locally advanced cancer of the esophagus and GE junction. Journal Of Clinical Oncology 2012, 30: 74-74. DOI: 10.1200/jco.2012.30.4_suppl.74.Peer-Reviewed Original ResearchSquamous carcinomaGrade 3 non-hematological toxicityOpen-label phase IOperable esophagealFox Chase Cancer CenterNon-hematological toxicitiesPathologic complete responsePhase I evaluationAST/ALTPromising clinical activityEsophageal squamous carcinomaPET/CTCarboplatin AUC5Male ptsAbdominal painCurative intentGI hemorrhageInduction chemoradiotherapyInduction therapyDistant recurrenceInduction chemoradiationMedian followupComplete responseAdvanced cancerDose escalation